Lupin Analyst Review May 2026

This Lupin analyst review for May 2026 covers the key data investors need for LUPIN at its current price of Rs 2,200. Lupin (NSE: LUPIN) is one of India’s largest pharmaceutical companies with a market capitalisation of approximately Rs 1,00,000 crore, with strong positions in branded generics in India and the US generics market. The analyst consensus target of Rs 2,600 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether LUPIN achieves that target through FY27.

Click Here – Get Free Investment Predictions

Lupin Company Snapshot May 2026

Lupin’s specialty business in the US (spirometry inhalers, oral contraceptives) and its branded Indian prescription business in respiratory, cardiovascular, and anti-infectives are growing well. A biosimilar filing pipeline for the US market is an emerging catalyst. The table below summarises the key data referenced in this Lupin analyst review.

Parameter	Value
NSE Ticker	LUPIN
Sector	Pharmaceuticals
CMP (May 2026)	Rs 2,200
52 Week High	Rs 2,600
52 Week Low	Rs 1,700
Market Cap	Rs 1,00,000 Crore
Trailing P/E	30.00x
Analyst Consensus Target	Rs 2,600
Bull Case Target	Rs 3,000
Bear Case Target	Rs 1,800

Analyst Insight in This Lupin Analyst Review

Associate Director Kunal Singla suggests watching Lupin closely in May 2026. At the current market price of Rs 2,200, Kunal Singla flags Pharmaceuticals sector dynamics as a key driver for LUPIN’s near-term price action. He notes support in the Rs 1,734 to Rs 2,090 zone and flags any sustained close above Rs 2,332 as a positive signal worth tracking. Kunal Singla’s perspective on Lupin adds a layer of professional technical analysis to this Lupin analyst review and is not a buy recommendation.

Technical Analysis in This Lupin Analyst Review

At Rs 2,200, LUPIN is trading within its 52-week band of Rs 1,700 to Rs 2,600. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 1,734 to Rs 2,090 band while resistance is seen in the Rs 2,332 to Rs 2,400 zone. A sustained move above Rs 2,332 could open the path toward the analyst consensus of Rs 2,600.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 1,734 to Rs 2,090 – investors tracking this Lupin analyst review should watch for a stabilisation or bounce in this range as a potential accumulation signal.
• Resistance Zone: Rs 2,332 to Rs 2,400 – a sustained close above Rs 2,332 would be a positive breakout signal worth flagging.
• Medium-Term Target: The analyst consensus of Rs 2,600 represents the base-case upside for this Lupin analyst review.

Business Segment Analysis

US Generics (Inhalers, Oral Contraceptives)

This is the primary revenue and margin driver for Lupin, directly supporting the earnings trajectory toward the consensus target of Rs 2,600.

India Branded Prescription Business (Respiratory, CV)

This segment adds scale and diversification to Lupin’s business model and is a meaningful EPS contributor through FY27 and FY28.

Biosimilars and Specialty Products Pipeline

This represents the medium-term growth frontier for Lupin and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Lupin Analyst Review

At Rs 2,200, Lupin trades at a trailing P/E of 30.00x. This Lupin analyst review presents three scenarios: a bull case of Rs 3,000 on strong earnings delivery, a base case of Rs 2,600 at consensus, and a bear case of Rs 1,800 if macro headwinds persist. Q1 FY27 results will be the first key validation point.

Scenario	Target Price	Key Condition
Bull Case	Rs 3,000	Strong earnings and sector tailwinds
Base Case (Consensus)	Rs 2,600	Moderate growth, analyst consensus estimate
Bear Case	Rs 1,800	Earnings miss or macro headwinds

Trade Outlook for Lupin

Based on the technical and fundamental analysis in this Lupin analyst review, investors might watch LUPIN near the support zone of Rs 1,734 to Rs 2,090 for potential opportunities. A flag above Rs 2,332 could suggest improving momentum toward Rs 2,600. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Lupin in FY27

A well-rounded Lupin analyst review must assess downside risks. Key risks for Lupin include a macro slowdown affecting Pharmaceuticals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in LUPIN.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Lupin Analyst Review Verdict for 2026

This Lupin analyst review concludes that at Rs 2,200, LUPIN offers a defined risk-reward with a consensus target of Rs 2,600. The 52-week range of Rs 1,700 to Rs 2,600 provides context on the current entry point. Use this Lupin analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on LUPIN.

Frequently Asked Questions: Lupin Analyst Review 2026

What is the analyst target for Lupin in 2026?

The analyst consensus target is Rs 2,600, with a bull case of Rs 3,000 and a bear case of Rs 1,800. Monitor Q1 FY27 earnings for confirmation.

Is Lupin a good investment at Rs 2,200?

At Rs 2,200 with a P/E of 30.00x and a consensus target of Rs 2,600, this Lupin analyst review is constructive for medium to long-term investors in the Pharmaceuticals sector. Always consult a SEBI-registered advisor before investing.

What is Lupin’s 52-week high and low?

The 52-week high is Rs 2,600 and the 52-week low is Rs 1,700. At Rs 2,200, LUPIN is positioned within this range as noted in this Lupin analyst review.

What are the key risks for Lupin?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals sector.

Where can I get live data and analyst targets for Lupin?

Track Lupin’s live price and analyst targets on the Univest Screener alongside professional financial advice.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.